Skip to content
MARKETS / NASDAQ / IRMD
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Iradimed Corp. IRMD

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$83.8M
▲ 14.4% YoY
$22.5M
▲ 16.9% YoY
$17.2M
▼ 2.5% YoY
In brief

What this company does

IRADIMED CORPORATION develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible medical devices and related accessories, disposables and services relating to them. The company was originally incorporated in Oklahoma under the name IRI Development, Inc. in 1992, and it merged its Oklahoma corporation into the newly formed Delaware corporation, IRADIMED CORPORATION, in April 2014. It is the only known provider of a non-magnetic intravenous (IV) infusion pump system that is specifically designed to be safe for use during MRI procedures and operates dependably in magnetic fields up to 15,000 gauss. It sells its products primarily to hospitals and acute care facilities, both in the United States and internationally. Internationally, it markets its products into approximately 80 countries through the use of independent distributors. As of December 31, 2025, the company had 166 full-time employees, including 55 in manufacturing and service, 68 in sales, marketing and customer support services, 14 in regulatory affairs and quality assurance, 14 in finance and administration and 15 in research and development.

Written from the business description in IRADIMED CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 6 March 2026. Every sentence was checked against that document before publication.

Growth
USD 83.8M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 83.8 · Net income 22.5
40M80M2013201520172019202120232025
Compound annual growth
+16.3%
+21.5%
+10.2%
+20.6%
+75.0%
+11.6%
+19.7%
+73.9%
+11.3%
+6.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +21.5% a year over five years — but profit grew faster: net income at +75.0%, earnings per share at +73.9%.

The share count rose from 0.01B to 0.01B over the period.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
27 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 31.2% · Net 26.8%
10%20%30%2013201520172019202120232025
ROE
FY2025 · ROE 24.8%
10%20%30%2013201520172019202120232025

Each USD of equity produced 25 cents of profit this year.

Cash & shareholders
USD 15.0M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 17.2
8M16M2013201520172019202120232025
Net buybacks $M Dividends $M
FY2025 · Dividends 15.0 · Net buybacks —
8M201620172022202320242025

USD 15.0M in dividends — 67% of the year's profit went back to shareholders.

Total assetsUSD 108.8M
EquityUSD 94.6M
CashUSD 51.2M
Current ratio7.98×

Equity funds 87% of total assets.

The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.10.10.10.10.00.00.00.00.00.00.00.00.0
Operating income $B0.00.00.00.00.0−0.00.00.00.00.00.00.00.0
EBITDA $B0.00.00.00.00.00.00.00.00.00.00.00.00.0
Income tax $B0.00.00.00.00.0−0.0−0.0−0.00.00.00.00.00.0
Net income $B0.00.00.00.00.00.00.00.00.00.00.00.00.0
Free cash flow $B0.00.00.00.00.00.00.00.00.00.00.00.00.0
EPS, diluted $1.751.501.351.020.740.110.780.520.040.600.600.200.22
Dividend / sh $·············
Payout %67717798·········
ROE %24.824.323.717.614.02.319.816.81.522.628.515.635.7
Shares out B0.010.010.010.010.010.010.010.010.010.010.010.010.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 65 reconciliationsAUDITED

Reconciled in 13 of 19 fiscal years. 30 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image